CA2661546A1 - Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same - Google Patents

Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same Download PDF

Info

Publication number
CA2661546A1
CA2661546A1 CA002661546A CA2661546A CA2661546A1 CA 2661546 A1 CA2661546 A1 CA 2661546A1 CA 002661546 A CA002661546 A CA 002661546A CA 2661546 A CA2661546 A CA 2661546A CA 2661546 A1 CA2661546 A1 CA 2661546A1
Authority
CA
Canada
Prior art keywords
day
therapeutically effective
effective amount
vitamin
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002661546A
Other languages
English (en)
French (fr)
Inventor
Alan H. Auerbach
Arie S. Belldegrun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Oncology Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA2838089A priority Critical patent/CA2838089A1/en
Publication of CA2661546A1 publication Critical patent/CA2661546A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/5939,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002661546A 2006-08-25 2007-08-23 Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same Abandoned CA2661546A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2838089A CA2838089A1 (en) 2006-08-25 2007-08-23 Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93492406P 2006-08-25 2006-08-25
US60/934,924 2006-08-25
PCT/US2007/018770 WO2008024485A2 (en) 2006-08-25 2007-08-23 Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2838089A Division CA2838089A1 (en) 2006-08-25 2007-08-23 Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same

Publications (1)

Publication Number Publication Date
CA2661546A1 true CA2661546A1 (en) 2008-02-28

Family

ID=39107444

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002661546A Abandoned CA2661546A1 (en) 2006-08-25 2007-08-23 Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
CA2838089A Abandoned CA2838089A1 (en) 2006-08-25 2007-08-23 Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2838089A Abandoned CA2838089A1 (en) 2006-08-25 2007-08-23 Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same

Country Status (9)

Country Link
EP (2) EP2063963A2 (cg-RX-API-DMAC7.html)
JP (1) JP2010501576A (cg-RX-API-DMAC7.html)
KR (1) KR20090060306A (cg-RX-API-DMAC7.html)
CN (1) CN101528309A (cg-RX-API-DMAC7.html)
AU (1) AU2007287099A1 (cg-RX-API-DMAC7.html)
CA (2) CA2661546A1 (cg-RX-API-DMAC7.html)
IL (1) IL197212A0 (cg-RX-API-DMAC7.html)
NO (1) NO20091191L (cg-RX-API-DMAC7.html)
WO (1) WO2008024485A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20170434A (es) * 2009-01-27 2017-11-21 Berg Llc VITAMINA D3 Y ANALOGOS DE LA MISMA PARA ALIVIAR EFECTOS SECUNDARIOS ASOCIADOS CON LA QUIMIOTERAPIA. (Divisional 2011-0445)
KR101360725B1 (ko) 2009-06-26 2014-02-07 노파르티스 아게 Cyp17의 억제제로서의 1,3-이치환된 이미다졸리딘-2-온 유도체
WO2011007208A1 (en) * 2009-07-16 2011-01-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compounds and methods for the treatment of cancer
EP2627648A1 (en) 2010-09-16 2013-08-21 Novartis AG 17aHYDROXYLASE/C17,20-LYASE INHIBITORS
US20120116381A1 (en) 2010-11-05 2012-05-10 Houser Kevin L Surgical instrument with charging station and wireless communication
JP6002210B2 (ja) 2011-04-28 2016-10-05 ノバルティス アーゲー 17α−ヒドロキシラーゼ/C17,20−リアーゼ阻害剤
US9801844B2 (en) * 2012-05-24 2017-10-31 The Research Foundation Of The City University Of New York Methods and compositions for the treatment of cancer
EA030128B1 (ru) 2012-09-26 2018-06-29 Арагон Фармасьютикалз, Инк. Способ лечения неметастатического кастрационно-резистентного рака простаты
WO2014058785A1 (en) 2012-10-10 2014-04-17 Novartis Ag Combination therapy
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
MX2015014701A (es) 2013-04-24 2016-08-08 Salk Inst For Biological Studi Circuito genomico del receptor de vitamina d/smad que regula la compuerta de la respuesta fibrotica.
EP3473299A1 (en) 2013-06-05 2019-04-24 Salk Institute for Biological Studies Vitamin d receptor agonists to treat diseases involving cxcl12 activity
WO2019023149A1 (en) 2017-07-24 2019-01-31 Salk Institute For Biological Studies USE OF BROMODOMAIN-CONTAINING PROTEIN-9 ANTAGONISTS IN ASSOCIATION WITH VITAMIN D RECEPTOR AGONISTS IN THE TREATMENT OF DIABETES
KR20240096623A (ko) 2017-10-16 2024-06-26 아라곤 파마슈티컬스, 인코포레이티드 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120722A (en) 1984-02-08 1992-06-09 Hoffmann-La Roche Inc. Trihydroxy-cholecacliferol and trihydroxy-ergocalciferol for treating leukemia
US4857518A (en) 1984-10-04 1989-08-15 Wisconsin Alumni Research Foundation Hydroxylated 24-homo-vitamin D derivatives and methods for preparing same
US4717721A (en) 1985-05-30 1988-01-05 Howard W. Bremer Sidechain homo-vitamin D compounds with preferential anti-cancer activity
US4866048A (en) 1985-08-02 1989-09-12 Leo Pharmaceutical Products Ltd. Novel vitamin D analogues
US5145846A (en) 1988-01-20 1992-09-08 Hoffmann-La Roche Inc. Vitamin D3 analogs
US4851401A (en) 1988-07-14 1989-07-25 Wisconsin Alumni Research Foundation Novel cyclopentano-vitamin D analogs
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
GB8915770D0 (en) 1989-07-10 1989-08-31 Leo Pharm Prod Ltd Chemical compounds
DE4101953A1 (de) 1991-01-19 1992-07-23 Schering Ag 23-oxa-derivate in der vitamin-d-reihe, verfahren zu ihrer herstellung diese derivate enthaltende pharmazeutische praeparate sowie deren verwendung als arzneimittel
DE4141746A1 (de) 1991-12-13 1993-06-17 Schering Ag 20-methyl-substituierte vitamin d-derivate
DE69327096T2 (de) * 1992-03-31 2000-06-21 Btg International Ltd., London 17-substituierte steroide, verwendbar bei behandlung von krebs
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5547947A (en) 1993-03-11 1996-08-20 Hoffmann-La Roche Inc. Methods of treatment
GB9622590D0 (en) 1996-10-30 1997-01-08 Leo Pharm Prod Ltd Chemical compounds
US6521608B1 (en) 1998-03-27 2003-02-18 Oregon Health & Science University Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders
EP1276482B1 (en) * 2000-03-02 2008-01-16 University Of Pittsburgh Of The Commonwealth System Of Higher Education Combination chemotherapy
US7094775B2 (en) * 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents

Also Published As

Publication number Publication date
WO2008024485A2 (en) 2008-02-28
AU2007287099A1 (en) 2008-02-28
CA2838089A1 (en) 2008-02-28
JP2010501576A (ja) 2010-01-21
NO20091191L (no) 2009-03-23
EP2063963A2 (en) 2009-06-03
KR20090060306A (ko) 2009-06-11
WO2008024485A3 (en) 2009-03-05
EP2425874A3 (en) 2013-05-15
EP2425874A2 (en) 2012-03-07
CN101528309A (zh) 2009-09-09
IL197212A0 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
US10702540B2 (en) Methods and compositions for treating cancer
CA2661546A1 (en) Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
CA2661422C (en) Methods and compositions for treating cancer
US20110021470A1 (en) Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
US20110319369A1 (en) Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent
HK1173966A (en) Compositions for treating cancer

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20151014